BeyondSpring presents clinical data showing Plinabulin reduces thrombocytopenia
BeyondSpring presented clinical trial data on its novel lead asset, Plinabulin, during a poster presentation at theWorld Conference on Lung Cancer in Toronto, Canada. New data from the company's Phase 2 portion of the Phase 2/3 trial in Study 105 of Plinabulin was presented. Thrombocytopenia, a frequent side effect of chemotherapy, is a lowering of platelet counts that, when severe, leads to bleeding and anemia and can require transfusion with platelets, potentially resulting in a long ICU stay, as well as a high mortality rate. In a head-to-head Phase 2 trial comparing Plinabulin with Neulasta, a long-acting G-CSF, Plinabulin at 20 mg/m2 was shown to be effective in significantly reducing docetaxel-induced thrombocytopenia, while Neulasta did not show this benefit.